AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to Cheplapharm in the US and Canada

 AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to Cheplapharm in the US and Canada

AstraZeneca Divests Commercial Rights of Seroquel and Seroquel XR to Cheplapharm in the US and Canada

Shots:

  • AstraZeneca to receive $35M upfront with future sales-contingent payments of up to $6M and it continues to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period
  • The divestiture will allow AstraZeneca to focus on its main therapeutic areas by reducing its portfolio of mature medicines. In earlier 2019, AstraZeneca divested the rights of these atypical antipsychotic therapies to Cheplapharm in EU (Ex- UK) and Russia
  • Seroquel & Seroquel XR are anti-psychotic therapies with antidepressant properties indicated to treat schizophrenia and bipolar disorder and has generated $36M & $79M revenue in 2018 in the US and Canada respectively

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Delaware online

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post